Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioArctic | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 20.17B | -87.1x | 0.43 | SEK 228.20 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.4% Upside | Upgrade to Pro+ | |
Medivir B | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 3.64B | -0.1 | SEK 2.83 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Hansa Biopharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.25B | -3x | -0.1 | SEK 33.22 | 4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Egetis Therapeutics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.17B | -5.5x | -0.32 | SEK 6.05 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vicore Pharma Holding AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.15B | -5.2x | -0.25 | SEK 9.16 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Devyser Diagnostics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.12B | -26.3x | 1.3 | SEK 128.50 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.8% Upside | Upgrade to Pro+ | |
Diamyd Medical | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.79B | -10.8x | 1.51 | SEK 17.18 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioInvent International | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.78B | -4.4x | 0.16 | SEK 27.05 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cereno Scientific | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.47B | -19.6x | 0.36 | SEK 5.22 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
XSpray Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.26B | -4.2x | 1 | SEK 34.05 | 8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nanoform Finland Plc | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.21B | -4.9x | 1.56 | SEK 13.76 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intellego Technologies AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.06B | 13.8x | 0.14 | SEK 37.25 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nykode Therapeutics | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 890.71M | -1.9x | SEK 13.98 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Saniona AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 879.42M | -9.1x | -0.35 | SEK 7.86 | 15.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.9% Upside | Upgrade to Pro+ | |
Abliva AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 704.39M | -6x | -0.57 | SEK 0.44 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SynAct Pharma AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 678.07M | -2.7x | -0.18 | SEK 13.90 | 10.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Hamlet Pharma AB | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 526.78M | -12.8x | 0.66 | SEK 3.14 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Initiator Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 398.56M | -23.7x | -0.41 | SEK 7.10 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Promimic AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 397.40M | -34.3x | 1.98 | SEK 21.30 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mendus AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 365.11M | -2.4x | -0.05 | SEK 7.25 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Peptonic Medical | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 345.56M | -0.4x | -0.01 | SEK 0.004 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Guard Therapeutics | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 341.80M | -3.3x | -0.07 | SEK 27.80 | 17.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cantargia AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 339.64M | -1.8x | -0.04 | SEK 1.85 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oncopeptides | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 310.30M | -0.7x | -0.04 | SEK 1.44 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Curasight AS | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 299.25M | -7.2x | 0.4 | SEK 14.44 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascelia Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 274.86M | -2x | -0.07 | SEK 2.86 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xbrane Biopharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 274.70M | -0.4x | -0.01 | SEK 0.18 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alzinova | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 251.45M | -8.3x | -0.66 | SEK 2.82 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Annexin Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 246.24M | -3.2x | -0.12 | SEK 0.46 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xintela | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 237.74M | -5.8x | -0.11 | SEK 0.42 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SenzaGen | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 216.85M | -10.6x | -0.47 | SEK 7.35 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NextCell Pharma AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 210.50M | -2.8x | -0.43 | SEK 2.88 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biovica International | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 205.35M | -1.5x | -0.03 | SEK 2.10 | -8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Prolight Diagnostics | NGM | Healthcare | Biotechnology & Medical Research | SEK 173.42M | -0.9x | 0 | SEK 0.25 | 8.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Acousort | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 146.06M | -7.6x | 0.29 | SEK 9.78 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Klaria Pharma Holding AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 143.31M | -2.8x | -0.18 | SEK 0.99 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.2% Upside | Upgrade to Pro+ | |
AroCell | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 134.76M | -2.6x | -0.2 | SEK 0.59 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Active Biotech | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 130.40M | -0.9x | -0.09 | SEK 0.11 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kancera AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 127M | -2x | -0.07 | SEK 1.05 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AlzeCure Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 124.50M | -2.8x | -0.18 | SEK 1.41 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lumito AB | NGM | Healthcare | Biotechnology & Medical Research | SEK 122.31M | -3.3x | -5.47 | SEK 0.49 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biosergen AS | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 121.73M | -2.3x | -0.09 | SEK 0.52 | 6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sprint Bioscience AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 108.22M | -5.7x | 0.08 | SEK 1.55 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Coegin Pharma AB | NGM | Healthcare | Biotechnology & Medical Research | SEK 94.80M | -2x | -0.08 | SEK 4.35 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Spago Nanomedical AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 91.92M | -1.8x | -0.03 | SEK 0.26 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dextech Medical | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 73.94M | -15.3x | 6.21 | SEK 4 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bio-Works | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 72.50M | -0.9x | -0.05 | SEK 0.93 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intervacc | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 70.06M | -0.9x | -0.02 | SEK 0.93 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abera Bioscience | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 58.95M | -15.2x | -0.19 | SEK 3.84 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Modus Therapeutics Holding AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 48.52M | -2.9x | -0.05 | SEK 1.35 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |